An observational study in Brest Cancer, Lung Cancer (NSCLC) and Pancreatic Cancer, Adult, sponsored by Javier Toledo. Recruiting at 4 sites in 3 countries. Open to participants aged 40 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-02.
Sponsored by Javier Toledo · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 276 studies in Lung Neoplasms with a site in United Kingdom — 58 open to participants now, 83 under way, 24 of them phase 3. Lung Neoplasms · United Kingdom.
Among the 276 studies in Lung Neoplasms with a site in United Kingdom, this one is the 8th largest by planned enrollment of the 71 observational ones that give a count, is one of 23 that started in 2025, is one of 71 observational ones, reaches primary completion later than 44 of the 82 other live ones, and was the 249th registered.
5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.
Browse Lung Neoplasms studies →58 of the 276 studies in Lung Neoplasms with a site in United Kingdom are open now. Recruiting first, the newest first:
Intuitive Surgical · Sites in United Kingdom, Germany, Switzerland
Ages 18+
Boehringer Ingelheim · Sites in United Kingdom, Australia, China and 5 more countries
Ages 18+
Queen's University, Belfast · Sites in United Kingdom
Ages 18+
NHS Greater Glasgow and Clyde · Sites in United Kingdom
Ages 18+
University of Edinburgh · Sites in United Kingdom, Norway
Ages 18+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.
This study: 40 Years to 75 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
276 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 43 · Phase 2 72 · Phase 3 75 · Phase 4 2
First in 1993; this study’s year is marked. 23 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 6,000 is above the median of 200 across 1,436 observational studies indexed under Lung Neoplasms.
Median enrollment 200 across the 197 interventional studies, 400 across the 71 observational. Of the 146 that completed or were terminated, 41 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
124 of 276 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Javier Toledo as lead sponsor.
Javier Toledo has 1 study filed under Lung Neoplasms — fewer than ten, so there is no comparison to draw.
23 of the studies in Lung Neoplasms with a site in United Kingdom that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06151574Phase 3Boehringer IngelheimBeamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment | 2026-12-10 |
| NCT04380636Phase 3Merck Sharp & Dohme LLCStudy of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012) | 2027-05-05 |
| NCT05920356Phase 3AmgenA Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) | 2027-06-30 |
| NCT06635824Phase 3GenmabTrial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06) | 2027-07-30 |
| NCT06119581Phase 3Eli Lilly and CompanyA Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer | 2027-11 |
Add all 23 to your calendar (.ics) → With an account.
Among the 276 studies in Lung Neoplasms with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the CCANED-CIPHER study is to develop and validate an AI-based blood test for early cancer detection and to monitor treatment effectiveness in cancer patients. This two-phase, multi-center observational study aims to identify specific transcriptomic biomarkers in platelets and immune cells that distinguish cancer patients from healthy individuals and correlate with treatment outcomes. By analysing blood samples using artificial intelligence, the study seeks to create a safe, non-invasive method to enhance cancer diagnosis and monitor treatment responses over time.
The CCANED-CIPHER study aims to revolutionise cancer diagnostics and treatment monitoring by developing and evaluating an AI-based early cancer detection tool that profiles RNA biomarkers from platelets and immune cells in blood samples. This non-invasive approach leverages liquid biopsy methods to enhance early cancer detection and provide insights into therapeutic responses.
Phase 1 (Common Cancer Early Detection [CCANED]): Early Cancer Detection
Objective:
To identify specific platelet-derived RNA biomarkers that can distinguish individuals with common cancers from healthy controls using AI-driven transcriptomic analysis.
Methodology:
Laboratory Analysis:
Data Analysis:
Expected Outcomes:
Phase 2 ( Cancer Immuno-Profiling of Hematologic and Extracellular RNA [CIPHER]): Therapeutic Response Monitoring
Objective:
To evaluate how RNA biomarkers from immune cells and platelets correlate with therapeutic responses, providing insights into treatment efficacy and potential relapse.
Methodology:
Laboratory Analysis:
Data Analysis:
Expected Outcomes:
Significance of the Study
The CCANED-CIPHER study addresses critical needs in oncology by providing:
Expected Impact and Future Applications: The identification of specific RNA biomarkers from platelets and immune cells has the potential to transform current practices in oncology, offering a more efficient, accurate and patient-friendly approach to cancer care.
The CCANED-CIPHER study will enroll a diverse, geographically dispersed population to ensure the generalizability and robustness of its findings. The study is divided into two phases, utilizing up to 10 medical centers globally across the United Kingdom (UK), Europe, America, and Asia.
Phase 1 (CCANED):
Participants: 5,000 adults aged 40 years or older.
Recruitment Strategy: Participants will be identified and enrolled through the participating medical centers, ensuring a representative sample across different geographical locations.
Phase 2 (CIPHER):
Participants: 1,000 adults aged 40 years or older diagnosed with HCC or NSCLC across stages I to IV.
Recruitment Strategy: Cancer patients will be recruited from the participating cancer centers, ensuring a wide representation of disease stages and treatment backgrounds.
Phase 1 (Common Cancer Early Detection - CCANED)
Inclusion Criteria:
Exclusion Criteria:
Phase 2 ( Cancer Immuno-Profiling of Hematologic and Extracellular RNA - CIPHER)
Inclusion Criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This arm will include 3,500 individuals with confirmed diagnoses of common cancers such as Non-Small Cell Lung Cancer (NSCLC), Glioblastoma Multiforme (GBM), Colorectal Cancer, Hepatocellular Carcinoma (HCC), Breast Cancer, Prostate Cancer, Ovarian Cancer, and Pancreatic Cancer.
Diagnostic Test: DiNanoQ: A multi-cancer early detection (MCED) blood test
This arm will consist of 1,500 age- and sex-matched cancer-free individuals serving as controls.
Diagnostic Test: DiNanoQ: A multi-cancer early detection (MCED) blood test
This cohort will include 1,000 patients diagnosed with Hepatocellular Carcinoma (HCC) or Non-Small Cell Lung Cancer (NSCLC) across stages I to IV who are about to commence standard cancer therapy.
Diagnostic Test: DiNanoQ: A multi-cancer early detection (MCED) blood test · Other: DiNanoTrack: Therapeutic Response Monitoring Blood Test
Procedure: Participants will undergo a single blood draw at baseline. Sample Analysis: Platelet Isolation: Platelets will be extracted from the collected blood samples. RNA Analysis: RNA from the isolated platelets will be extracted and analyzed using AI-based transcriptomic profiling to identify biomarkers associated with cancer.
Procedures: Blood Sample Collection: Participants will have blood samples drawn at three time points: Baseline: Before therapy initiation. 6 Weeks Post-Therapy Initiation: To monitor early treatment response. 6 Months Post-Therapy Initiation: To assess longer-term therapeutic outcomes. Sample Analysis: Platelet and Immune Cell Isolation: Platelets: Extracted from each blood sample to continue monitoring RNA profiles. Immune Cells: Separated from the blood samples to analyse immune response to therapy. RNA Analysis: Platelet RNA: Analysed to observe changes in transcriptomic profiles over time using AI-based tools. Immune Cell RNA: Examined to assess transcriptomic changes associated with therapeutic responses. Data Correlation: Therapeutic Response Assessment: RNA profiles from platelets and immune cells will be correlated with clinical outcomes to identify biomarkers predictive of treatment efficacy, progression-free survival, relapse, and drug resistance.
Identification of Platelet RNA Biomarkers Distinguishing Cancer Patients from Controls
Utilise AI-based transcriptomic analysis of platelet RNA to identify biomarkers that differentiate between cancer patients and cancer-free controls.
Time frame: Baseline (single time point)
Identification of RNA Biomarkers Correlating with Therapeutic Response (Phase 2)
Identify RNA biomarkers from immune cells and platelets that correlate with clinical treatment response, as measured by standard criteria (e.g., RECIST)
Time frame: Baseline to 6 months post-therapy initiation
Association Between Immune Cell Transcriptomes and AI-Based Platelet Signals
Evaluate how changes in immune cell transcriptomes are associated with signals detected by the AI-based platelet profiling tool.
Time frame: Baseline to 6 months post-therapy initiation
Sensitivity and Specificity of the AI-Based Diagnostic Tool (Phase 1)
Calculate the diagnostic accuracy of the AI-based tool in detecting cancer among participants.
Time frame: Baseline
Feasibility of Platelet Transcriptomic Profiling Implementation
Assess the practicality of sample collection, processing, and analysis in a clinical setting.
Time frame: Phase 1 - 2 years
Development of Predictive Models for Treatment Outcomes (Phase 2)
Create and validate predictive models that integrate platelet and immune cell RNA profiles to predict treatment response and progression-free survival.
Time frame: Phase 2 - Two years
Identification of Biomarkers Predictive of Relapse and Drug Resistance (Phase 2)
Identify RNA biomarkers predictive of relapse and drug resistance at the 6-month follow-up.
Time frame: Baseline to 6 months post-therapy initiation
Not enrolling at this site.
Plan to share: Undecided
Started Dec 2025 (actual). Primary completion is estimated for Aug 2027, 19 months after the start.
Of 90 industry-sponsored observational studies under Lung Neoplasms, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 58. This study's planned 19 months is below that.
Counting every sponsor, half of 682 studies reached it within 57 months; a quarter within 25 and three quarters within 135.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.